Press "Enter" to skip to content

T1D Stem Cell Trial Back On; Fifth Grade Obesity; Islet Autoantibodies Predictive

After being hit with a clinical hold, Vertex Pharmaceuticals announced it’s been given the FDA green-light to push forward on its phase I/II trial for the investigative type 1 diabetes stem cell treatment VX-880.

According to a 4-year study, kids who received medical nutrition therapy following a prediabetes diagnosis were less likely to progress to full-blown disease. (Frontiers in Endocrinology)

More and more kids — and particularly Black children — that enter kindergarten at normal weight are developing obesity by the end of fifth grade. (Pediatrics)

Initial screening for islet autoantibodies at ages 2 and 6 years was sensitive enough to predict type 1 diabetes onset in later childhood. (The Lancet Diabetes & Endocrinology)

The odds of conceiving without the use of fertility treatments may be lower for women living in socioeconomically disadvantaged neighborhoods. (JAMA Network Open)

A mouse study found that a rhythmic small intestinal gut microbiome achieved through time-restricted eating was able to prevent type 2 diabetes and obesity. (Cell Reports)

Transgender and gender expansive U.S. physicians said they commonly experience “overt and subtle biases” while practicing. (JAMA Network Open)

Survivors of differentiated thyroid cancer saw high rates of anxiety and depression, which were even more common in female patients with a higher BMI, permanent recurrent laryngeal nerve damage, and permanent hypoparathyroidism. (Thyroid)

  • Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.

Please enable JavaScript to view the comments powered by Disqus.

Source: MedicalNewsToday.com